PRND and ovarian cancer: Doppel level was found to be significantly higher in ovarian cancer patients than in healthy control (14.24 vs. 1.06 ng/mL) and the receiver operating characteristic (ROC) curve between control and ovarian cancer patients confirmed the performance and applicability of Doppel as a sera marker (Figure S4A,B).